ENTITY WIDE DISCLOSURES

12 Months Ended

Dec. 31, 2023

Entity Wide Disclosures [Abstract]

ENTITY WIDE DISCLOSURES

ENTITY WIDE DISCLOSURES

Operations By Geographic Location

The Company conducts operations in North America, Europe, Asia, South America, Africa and Australia through wholly-owned subsidiaries and representative sales offices. The Company attributes revenue to geographical locations based upon the location of the contracting entity. For the years ended December 31, 2023, 2022 and 2021, total revenue attributable to the U.S. represented approximately 98%, 98% and 97%, respectively, of total consolidated total revenue.

The following table summarizes property and equipment, net by geographic region and is further broken down to show countries which account for 10% or more of total as of December 31, if any (in thousands):

	2023		2022
Property and equipment, net:
United States	$	77,850	$	81,217
Europe
Belgium	18,190		11,778
Other	8,772		9,294
Total Europe	26,962		21,072
Asia-Pacific	14,472		6,223
Other	1,305		1,337
Total property and equipment, net	$	120,589	$	109,849

Revenue by Category

The following table disaggregates the Company’s revenue by major source (in thousands):

	Years Ended December 31,
	2023		2022		2021
Therapeutic Area
Oncology	$	587,097	$	467,796	$	362,846
Other	404,844		296,914		267,415
Metabolic	376,842		244,682		159,900
Cardiology	193,690		174,634		119,692
AVAI	163,312		118,031		110,976
Central Nervous System	160,057		157,939		121,548
Total revenue	$	1,885,842	$	1,459,996	$	1,142,377